PTAB Decision Not To Sanction Bass Shifts Focus To Capitol

By Ryan Davis (September 29, 2015, 1:29 PM EDT) -- The Patent Trial and Appeal Board's decision not to sanction controversial hedge fund manager Kyle Bass for challenging drug patents in America Invents Act reviews clears the way for similar challenges, unless Congress steps in to clamp down on who can file AIA petitions.

The board on Friday rejected a sanctions motion by Celgene Corp., a biopharmaceutical company with cancer drug patents in Bass' crosshairs. Celgene argued Bass is abusing the AIA process by targeting patents as a short-selling strategy aimed at driving down the price of the company's stock. The PTAB found that the AIA clearly allows anyone to file...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!